JNJ-Q2

JNJ-Q2
Systematic (IUPAC) name
7-[(3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid[1]
Clinical data
Routes of
administration
Oral, IV
Identifiers
ChemSpider 9721013 N
Chemical data
Formula C21H23F2N3O4
Molar mass 419.42 g/mol

JNJ-Q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically, JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.[2][3]

Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica, a unit of Johnson & Johnson, which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed.[4]

References

  1. "CSID:9721013". ChemSpider. Retrieved Aug 30, 2012.
  2. Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN (July 2011). "JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains". Antimicrob. Agents Chemother. 55 (7): 3631–4. doi:10.1128/AAC.00162-11. PMC 3122438. PMID 21555765.
  3. Morrow BJ, He W, Amsler KM, et al. (May 2010). "In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone". Antimicrob. Agents Chemother. 54 (5): 1955–64. doi:10.1128/AAC.01374-09. PMC 2863672. PMID 20176911.
  4. "Novel Fluoroquinolone (JNJ-Q2)". Furiex Pharmaceuticals.


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.